Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume 283, Issue 2, Pages 110-120
Publisher
Wiley
Online
2017-10-26
DOI
10.1111/joim.12708
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
- (2017) Kenji Chamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Emerging concepts of T cell metabolism as a target of immunotherapy
- (2016) Chih-Hao Chang et al. NATURE IMMUNOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- The Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo
- (2015) Julianna Blagih et al. IMMUNITY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell metabolism drives immunity
- (2015) Michael D. Buck et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting T cell metabolism for therapy
- (2015) David O'Sullivan et al. TRENDS IN IMMUNOLOGY
- T cell metabolic fitness in antitumor immunity
- (2015) Peter J. Siska et al. TRENDS IN IMMUNOLOGY
- Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
- (2015) A. Zippelius et al. Cancer Immunology Research
- Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage
- (2015) José Medina-Echeverz et al. Cancer Immunology Research
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Diisopropylamine Dichloroacetate, a Novel Pyruvate Dehydrogenase Kinase 4 Inhibitor, as a Potential Therapeutic Agent for Metabolic Disorders and Multiorgan Failure in Severe Influenza
- (2014) Kazuhiko Yamane et al. PLoS One
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Chemoimmunotherapy: reengineering tumor immunity
- (2013) Gang Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- AMPK: A metabolic switch for CD8+T-cell memory
- (2013) Koichi Araki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Evolution of oncolytic viruses: novel strategies for cancer treatment
- (2013) Matthew J Atherton et al. Immunotherapy
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
- (2013) Huafeng Wei et al. PLoS One
- Neuropilin-1Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment
- (2012) Usman Yaqoob et al. CANCER RESEARCH
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
- (2011) Alan Melcher et al. MOLECULAR THERAPY
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy
- (2010) Tsuguhide Takeshima et al. CANCER RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular Endothelial Growth Factor: Much More than an Angiogenesis Factor
- (2010) Donald R. Senger MOLECULAR BIOLOGY OF THE CELL
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
- (2010) Adam D. Cohen et al. PLoS One
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Systemic effects of local radiotherapy
- (2009) Silvia C Formenti et al. LANCET ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Transcriptional control of mitochondrial biogenesis: the central role of PGC-1
- (2008) R. Ventura-Clapier et al. CARDIOVASCULAR RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search